Serialisation has been widely talked about across the industry for some time. Despite this, many companies have failed to prioritise developing a solution meaning ensuring compliance come the various market deadlines is becoming increasingly difficult.

Next year, or even next week, is too late to start thinking about serialisation.

Many pharmaceutical companies are now turning to well-prepared contract manufacturing organisations (CMOs), like Recipharm, to help them tackle the challenges and ensure a robust process is in place.

In this roundtable with Manufacturing Chemist , Staffan Widengren, Director Corporate Projects at Recipharm discusses the urgency of serialisation and the impact the EU Falsified Medicines Directive (FMD) will have on the industry.

Read part one of the roundtable here